Shares of Atea Pharmaceuticals, Inc. (AVIR) declined 11.
Atea Pharmaceuticals (AVIR) has reported a wider-than-expected loss for the third quarter of 2021. Also, revenues missed analysts’ expectations.
Shares of Atea Pharmaceuticals (AVIR) plunged 66% on Tuesday to close at $13.82 after the clinical-stage biopharmaceutical company provided update and topline results …
Aviragen Therapeutics Inc (NASDAQ:AVIR) and Vaxart announced the signing of a definitive merger agreement, which will result in a combined company, Vaxart, Inc., …
